Oral Anticoagulation in Atrial Fibrillation: Are the Problems Solved?
Yükleniyor...
Dosyalar
Tarih
2010
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Aves Yayıncılık
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
The prevalence of atrial fibrillation (AF) is high and it is expected to increase in the near future (1). AF is a strong independent risk factor for ischemic stroke and systemic arterial embolisation (2). Oral anticoagulation (OAC) has been shown to decrease the risk of stroke. In a meta-analysis of 6 randomized trials including 2900 participants, the estimated relative risk reduction is reported as 64% (3). Despite the evident benefits, OAC is underused even in high-risk AF patients (4, 5). The study by Elezi et al. (6) provides an interesting retrospective analysis of the prescription of OACs in patients with AF in a single tertiary centre in Kosovo. The main finding is the low percentage of OAC use in patients with AF when compared with the previous studies. It is reported that only less than 1/3 of patients with primary or secondary diagnosis of AF were discharged on anticoagulation therapy. Elder age, normal left atrial size, and preserved ejection fraction were the independent predictors of underprescription of anticoagulants.
Açıklama
Anahtar Kelimeler
Kaynak
Anadolu Kardiyoloji Dergisi-the Anatolian Journal of Cardiology
WoS Q Değeri
Q4
Scopus Q Değeri
N/A
Cilt
10
Sayı
Künye
Doğan, U., (2010). Oral Anticoagulation in Atrial Fibrillation: Are the Problems Solved?. Anadolu Kardiyoloji Dergisi-the Anatolian Journal of Cardiology, (10), 41-42. Doi: 10.5152/akd.2010.009
